UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000005209
Receipt number R000006142
Scientific Title A phase ll study of Capecitabine plus Bevacizumab therapy for advanced/recurrent colo-rectal cancer with difficulty on intensive chemotherapy (OGSG 1102)
Date of disclosure of the study information 2011/04/01
Last modified on 2020/09/16 21:47:52

No. Disposal Last modified on Item of update
1 Insert 2011/03/07 19:50:03
2 Update 2011/08/10 19:21:35 Post marketing survey by drug manufacture etc., specified by Japanese law.
3 Update 2011/11/11 18:03:44 Recruitment status
4 Update 2011/11/22 19:15:42 Anticipated trial start date
Last follow-up date
5 Update 2012/06/24 22:50:45 Public title
Public title
Acronym
Acronym
6 Update 2012/06/24 22:55:20 Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Organization1
Address1
Tel1
Email1
7 Update 2012/09/07 22:05:32 Anticipated trial start date
Last follow-up date
8 Update 2014/03/08 04:03:20 Last follow-up date
9 Update 2014/07/27 23:10:44 Email
Email
Institutions
10 Update 2014/09/05 23:20:55 Institutions
11 Update 2014/09/05 23:22:18 Recruitment status
Last follow-up date
12 Update 2015/06/10 00:26:12 Email
Email
13 Update 2017/09/12 02:07:09 Name of primary person or sponsor
Organization
14 Update 2018/04/30 23:24:43 Email
Email
Organization
15 Update 2018/05/10 20:26:34 Email
Email
16 Update 2018/08/02 21:41:57 UMIN ID1
17 Update 2018/08/02 21:44:59 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Institute
18 Update 2020/01/05 14:50:10 Date of IRB
19 Update 2020/01/05 15:00:35 Date analysis concluded
20 Update 2020/09/16 21:47:52 Recruitment status